Nice to see, this was originally posted elswhere by

New Post Public Reply Private Reply Replies (0) Message Board
AlanC
Nice to see, this was originally posted elswhere by 4kids:

Hong Kong Tribunal Rules Against U.S. Short-Seller Andrew Left

Market Misconduct Tribunal finds Left was ‘reckless’ or ‘negligent’ in spreading information
WALL STREET JOURNAL
By JULIE STEINBERG
Updated Aug. 26, 2016 7:02 a.m. ET

HONG KONG—A Hong Kong tribunal found U.S. short-seller Andrew Left, best known for his critique of drug company Valeant Pharmaceuticals International Inc., was “reckless” or “negligent” for spreading false and misleading information about a Chinese property developer.

Hong Kong’s Market Misconduct Tribunal ruled in favor of the city’s securities regulator and against Mr. Left, a Los Angeles-based short seller who published a scathing report on Hong Kong-listed Evergrande Real Estate Group Ltd.—now called China Evergrande Group—in 2012.

The tribunal in its decision Friday said Mr. Left’s allegations of “insolvency” and “fraudulent accounting” at Evergrande were false, and that he should have checked with an expert and the company before publishing them. Mr. Left could face penalties, to be determined later, that include giving up his profits on the trade and a ban from trading for a period in Hong Kong.

The civil case, which the tribunal heard earlier this year, spotlights regulators’ concerns over analysts and traders who point to alleged problems at companies and bet that their share prices will fall. Some say short sellers benefit the market by digging up damaging information that might not otherwise surface. Others say they publish misleading comments to profit from driving down stock prices.

The debate over what constitutes allowable commentary has taken on particular urgency in Hong Kong in recent months. A different tribunal in March said ratings giant Moody’s Investors Service must pay 11 million Hong Kong dollars (US$1.4 million) because of errors and “misleading and unfair” language in a July 2011 report that highlighted “red flags” at certain Chinese companies. Moody’s is appealing the decision.

Shareholder activists say they fear such cases, which indicate closer scrutiny by regulators, could have a chilling effect on free speech in Hong Kong’s markets.

Mr. Left said in a phone interview he is considering an appeal. Hong Kong’s securities regulator in a press release thanked the U.S. Securities and Exchange Commission for its help with the case. The legal action is the first brought by the regulator against a short seller.

Mr. Left’s Citron Research publishes reports often peppered with profanity and taunts aimed at corporate executives. He frequently appears on U.S. business television channels to pan stocks, including a recent broadside against Facebook Inc. He says investors don’t fully appreciate the threat that the social-networking site faces from upstarts like Snapchat, and that Facebook isn’t worth its $353 billion market capitalization.

The 45-year-old Mr. Left lives in a mansion overlooking Los Angeles, across the street from Slash, the former lead guitarist of rock band Guns N’ Roses. Mr. Left invests only his own money and said he has made profits every year since he started short selling 15 years ago.

He gained prominence for his criticisms of Valeant’s accounting in October 2015, when he suggested that Valeant had used its relationship with a mail-order pharmacy to commit fraud. Valeant denied Mr. Left’s allegations, but the company has restated past earnings because of its relationship with the pharmacy. The Wall Street Journal has reported that Valeant is under criminal investigation.

Mr. Left’s criticisms contributed to a sharp decline in Valeant’s stock, which at one point had declined more than 90% from its high. Mr. Left had a short position in Valeant as recently as July, but he said Thursday that he doesn’t currently hold any position. A Valeant spokesman declined to comment.

In the Evergrande case, Mr. Left sold short 4.1 million shares of the company before publishing a report on his website on June 21, 2012, claiming the property developer was “insolvent” and had used “at least six accounting shenanigans to hide it.”

After publishing the report, Mr. Left bought back the shares for a total realized profit of HK$1.7 million. On the day the report was published, Evergrande’s share price fell as much as 20% before closing down 11.4% at 3.97 Hong Kong dollars (around 51 U.S. cents).

A spokesman on Friday couldn’t be reached, but Evergrande has denied the allegations in the past. Moody’s in January of this year downgraded the company’s debt deeper into junk territory amid concerns about the developer’s debt-funded growth strategy. Profit attributable to shareholders fell 17% in 2015 from a year earlier, while revenues were up 20%.

In its decision released Friday, the tribunal said Mr. Left’s allegations of accounting tricks “displayed a significant ignorance of the accountancy standards” Evergrande had to follow.

The tribunal said that when Mr. Left published his report on Evergrande, he “consciously disregarded the real risk” that it was “false and/or misleading as to material facts.”

Mr. Left didn’t consult an accounting expert regarding the allegations he made in the report, and didn’t contact the company before publishing, the tribunal said, thereby shirking his “obligation.” Mr. Left also “must have appreciated” his report’s impact on other investors, the tribunal wrote.

The tribunal is setting too high a bar for publishing commentary, Mr. Left said.

“What company would ever say ‘you’re right’?” when confronted with allegations of fraud, he said.

Mr. Left said the ruling was biased against short sellers. Bullish analysts haven’t been similarly charged for writing positive reports on stocks that later tanked, he said.

“If you don’t like my commentary, it’s reckless,” he said. “But if you do, it’s not.”

Lawyers for Hong Kong’s securities regulator and Mr. Left have three weeks to suggest appropriate penalties to the tribunal.

—Michael Rapoport contributed to this article.

Write to Julie Steinberg at julie.steinberg@wsj.com

http://www.wsj.com/articles/hong-kong-tribuna...1472185068

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 201

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 189

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 308

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 121

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 155

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 157

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 138

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 117

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

R. Scot Buell: From Oil Fields to Inner Excellence

Updated Category News Views 14

R. Scot Buell: A Catalyst in Petroleum Engineering So, here's the skinny on R. Scot Buell, a guy whose name rings bells in the petroleum engineering corridors. The Inner Circle's tip of the hat to him as a Pinnacle Professional Member Inner Circle of Excellence isn't just a ceremonial bash—it stamps on a career that has gone all out in the energy sector. What's this...

Continue Reading
Forbes Honors Check Point Software as Premier Cybersecurity Employer

Updated Category News Views 133

Check Point Software Achieves Remarkable Recognition Check Point Software Technologies Ltd. (NASDAQ: CHKP) has recently earned a prestigious accolade from Forbes, being named one of the World’s Best Employers for the fifth consecutive year. This recognition highlights the company's commitment not just to cybersecurity, but to creating an inspiring workplace for its...

Continue Reading
Coinbase CEO Predicts Bitcoin Will Reach $18 Trillion Market Value

Updated Category News Views 154

Bitcoin's Remarkable Ascent Towards $18 Trillion U.Today reports that Bitcoin (BTC) is increasingly seen as a superior monetary asset compared to traditional reserves like gold. The CEO of Coinbase (NASDAQ: COIN) emphasizes that Bitcoin has unique advantages that may lead it to achieve a staggering market valuation of over $18 trillion. Currently, Bitcoin's market value...

Continue Reading
Certara Unveils Innovative Non-Animal Testing Solution for Drug Developers

Updated Category News Views 127

Introducing Certara's Groundbreaking Non-Animal Navigator Solution In an exciting development for the pharmaceutical industry, Certara, Inc. (Nasdaq: CERT), a leading force in model-informed drug development, has launched its innovative Non-Animal Navigator solution. This new initiative is designed to help biopharmaceutical companies transition towards reduced reliance on...

Continue Reading
Dr. Gerard van Belle Takes Helm as Director of Science

Updated Category News Views 394

Dr. Gerard van Belle Appointed Director of Science at Lowell Observatory Dr. Gerard van Belle has officially taken the role of Director of Science at Lowell Observatory, managing a team tasked with groundbreaking astronomical exploration and innovation. Leading a New Era in Astronomy In this pivotal position, van Belle is set to guide a diverse group of astronomers and...

Continue Reading